SCHEMBL767083

SCHEMBL767083

C=C(C)c1ccccc1N1CCN(C(=O)C(=O)NCC(C)(C)O)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 7/20 0.44
KMT2A Q03164 3/20 0.38
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.38
PAX8 Q06710 1/20 0.38
GFER P55789 1/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EED O75530 1/20 0.38
ENPP2 Q13822 3/20 0.38
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
P4HB P07237 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10274111 0.85 RBP4 (0.50) RBP4KMT2ALMNAMEN1GFER
SCHEMBL766972 0.83 RBP4 (0.43) RBP4KMT2ALMNAMEN1PAX8
SCHEMBL632039 0.82 RBP4 (0.67) RBP4GFER
SCHEMBL10274552 0.75 GAA (0.43) RBP4KMT2AMEN1RAB9AGAA
SCHEMBL767464 0.74 RAB9A (0.39) RBP4KMT2ALMNATSHRSMN1; SMN2
SCHEMBL10274548 0.72 RAB9A (0.48) RBP4KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL766973 0.70 NOTUM (0.46) RBP4KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL767279 0.70 ALDH1A1 (0.43) KMT2AMEN1TSHRSMN1; SMN2EED
SCHEMBL10274113 0.69 AKR1C3 (0.45) RBP4KMT2ALMNAMEN1TSHR
SCHEMBL630598 0.69 RBP4 (0.78) RBP4KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES RBP4, RBP1, FABP4 RBP4 1/4885KMT2A 802/4885LMNA 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.